Hikma Pharmaceuticals PLC (LON:HIK)
1,473.00
+22.00 (1.52%)
Jun 19, 2026, 8:58 AM GMT
Hikma Pharmaceuticals Employees
Hikma Pharmaceuticals had 9,400 employees as of December 31, 2025. The number of employees decreased by 100 or -1.05% compared to the previous year.
Employees
9,400
Change (1Y)
-100
Growth (1Y)
-1.05%
Revenue / Employee
264.71K GBP
Profits / Employee
31.78K GBP
Market Cap
3.09B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 9,400 | -100 | -1.05% |
| Dec 31, 2024 | 9,500 | 400 | 4.40% |
| Dec 31, 2023 | 9,100 | 300 | 3.41% |
| Dec 31, 2022 | 8,800 | 100 | 1.15% |
| Dec 31, 2021 | 8,700 | 100 | 1.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Haleon | 24,535 |
| HUTCHMED (China) | 1,796 |
| Allergy Therapeutics | 584 |
| ECO Animal Health Group | 200 |
| Shield Therapeutics | 63 |
| Venture Life Group | 43 |
| Chill Brands Group | 11 |
| Provexis | 2 |
Hikma Pharmaceuticals News
- 14 days ago - U.S. Supreme Court Ends Amarin Patent Fight, Hikma Prevails - Nasdaq
- 14 days ago - Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma - PRNewsWire
- 14 days ago - Supreme Court Rules in Favor of Hikma Pharmaceuticals, Impacting Amarin (AMRN) - GuruFocus
- 14 days ago - US Supreme Court backs generic drugmaker in 'skinny label' patent case - Reuters
- 17 days ago - Hikma Pharmaceuticals Announces Major Expansion in Ohio, Creating 350 New Jobs and Investing $267 Million - GlobeNewsWire
- 2 months ago - Hikma Pharmaceuticals Transcript: Trading update - Transcripts
- 2 months ago - Hikma Pharmaceuticals Earnings release: Trading update - Filings
- 2 months ago - UK's Hikma Pharmaceuticals reiterates 2026 outlook despite higher costs from Iran war - Reuters